GSK Returns to India with Two Precision Cancer Therapies : Oncology Boom Incoming?

General
, , ,
1

GlaxoSmithKline is re-entering India’s oncology space with two new precision therapies for gynecological cancers: Jemperli and Zejula.

Is this the start of a cancer-care renaissance in Indian pharma?

Will more global pharma players follow suit and offer advanced oncology options?

Question to you:

Will this shift attract more clinical pharmacy roles in oncology, or will it remain physician led?

MBH/AB

3 Likes
2

This shift will likely attract more clinical pharmacy roles in oncology, as precision therapies require specialized pharmaceutical expertise for optimal patient care and treatment management.

3

GlaxoSmithKline (GSK) on announced its foray into the Indian oncology market with the launch of two precision therapies — Jemperli (dostarlimab) and Zejula (niraparib) — aimed at treating gynaecological cancers, one of the most common forms of cancer among women.Jemperli has become India’s first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) advanced endometrial cancer. Zejula, on the other hand, is the only once-daily oral PARP inhibitor approved as first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer.

4

This move by GSK is a big step for cancer care in India. Precision therapies like Jemperli and Zejula show that pharma is finally focusing on targeted treatment. If more global companies follow, we might see better options for patients. But for clinical pharmacists to play a bigger role, we need proper training and recognition. Right now, it’s mostly physician-led, but things can change if we push for it. Let’s hope this opens new doors.

5

Big development that GSK has re-entered India’s cancer treatment space by launching two precision therapies Jemperli (for advanced endometrial cancer) and Zejula (a once-daily maintenance pill for ovarian cancer). The company aims to make these accessible through tiered pricing and supportive programs to help patients manage costs and care.

6

I think it can attract more clinical pharmacology roles .